Products Affected - Description

• • Semglee Pen subcutaneous injection, Biocon, 100 units/mL, 3 mL pen injector, 5 count, NDC 83257-0012-33
  • Insulin glargine-yfgn, recombinant subcutaneous injection, Biocon, 100 units/mL, 3 mL pen injector, 5 count, NDC 83257-0015-32

Reason for the Shortage

• • Biocon states the reason for the shortage is increased demand.
  • Lilly has Basaglar and Rezvoglar available.
  • Sanofi has Lantus and Toujeo available.
  • Winthrop has insulin glargine injection available.

Available Products

• • Basaglar Kwikpen subcutaneous injection, Lilly USA, LLC, 100 units/mL, 3 mL pen injector, 5 count, NDC 00002-7715-59
  • Basaglar Tempo Pen subcutaneous injection, Lilly USA, LLC, 100 units/mL, 3 mL pen injector, 5 count, NDC 00002-8214-05
  • Insulin Glargine U-300 Max Solostar subcutaneous injection, Winthrop, 300 units/mL, 3 mL pen injector, 2 count, NDC 00955-2900-02
  • Insulin Glargine U-300 Solostar subcutaneous injection, Winthrop, 300 units/mL, 1.5 mL pen injector, 3 count, NDC 00955-3900-03
  • Lantus subcutaneous injection, Sanofi-Aventis, 100 units/mL, 10 mL vial, NDC 00088-2220-33
  • Lantus Solostar Pen subcutaneous injection, Sanofi-Aventis, 100 units/mL, 3 mL pen injector, 5 count, NDC 00088-2219-05
  • Rezvoglar Kwikpen subcutaneous injection, Lilly USA, LLC, 100 units/mL, 3 mL pen injector, 5 count, NDC 00002-8980-05
  • Semglee subcutaneous injection, Biocon, 100 units/mL, 10 mL vial, NDC 83257-0011-11
  • Toujeo 1.5 mL Prefilled Pen subcutaneous injection, Sanofi-Aventis, 300 units/mL, 1.5 mL pen injector, 3 count, NDC 00024-5869-03
  • Toujeo Max 3 mL Prefilled Pen subcutaneous injection, Sanofi-Aventis, 300 units/mL, 3 mL pen injector, 2 count, NDC 00024-5871-02
  • Insulin glargine-yfgn, recombinant subcutaneous injection, Biocon, 100 units/mL, 10 mL vial, NDC 83257-0014-11

• • Biocon has insulin glargine-yfgn 3 mL pens and Semglee 3 mL pens on back order and the company estimates a release date of early-March 2025.